UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Life Science

Human Genomic Evidence: Revolutionising the identification and prioritisation of targets for better medicines

Nine out of 10 potential drugs that enter clinical trials never make it to the market. Failure often occurs because the biological target chosen is not well understood. However, it is hard to objectively select targets with a high chance of clinical success because the data required to predict efficacy and safety are complex, dispersed and incomplete. To address this challenge, Open Targets was founded in 2014 as a public-private partnership by GSK, EMBL-EBI and the Wellcome Sanger Institute. The consortium has grown since its launch, welcoming new partners Biogen in 2016, Takeda in 2017, and Celgene in 2018.

Read More

Open Letter: Emma Taylor, CEO and Founder, Naked Biome

Dear colleagues.

Acne is the most common skin condition in the USA, affecting 85% of the world’s population over their lifetime and approximately 50 million people in the USA each year.

Read More

8 Free Tools for Genetic Engineers, Molecular and Synthetic Biologists

Having a powerful set of tools is essential in life science research so we’ve compiled the best free platforms for genetic engineers, molecular and synthetic biologists.

Read More

Transforming Drug Discovery by Accelerating the Development of More Effective Therapies

This article was originally published by Technology Networks in August 2018 and is published here with permission.

John Baldoni currently heads up a drug discovery unit at GlaxoSmithKline. Since joining GSK in 1989, John has held numerous positions within the company and has led many significant cross-functional strategic initiatives. He has an impressive 37 years’ experience working within the biopharmaceutical industry.

The recently established Accelerating Therapeutics for Opportunities in Medicine consortium, was conceived by John, with a mission “to accelerate the development of more effective therapies for patients”. ATOM stemmed from the Cancer Moonshot, an initiative that aims to improve the availability of cancer therapies, enhance detection of cancer early on, and improve our ability to prevent cancer.

Read More

Open Letter: Richard Gallo, Professor of Dermatology UCSD

Dear Colleagues,

Over recent years, we have seen record numbers of skin cancer diagnoses around the world. Indeed, since the 1980s, incidences of melanoma, the deadliest form of cancer, have doubled. Melanoma is an aggressive form of cancer that can spread to other organs and is estimated it will kill 10,000 people in the US this year. Approximately 3 million Americans will be diagnosed with skin cancer this year in the US.

Read More

Exploring the World’s Largest Biobanks

There are currently more than 120 biobanks worldwide. While most focus on genomic research and personalised medicine, biobanks range in size. Small operations have just a few freezers which are kept in a researcher’s laboratory, a clinical laboratory, or a pathology suite, while the larger, commercial ones support large clinical and epidemiological suites. In addition, the storage of samples tends to vary:

Read More

From data to discovery – the journey to digital innovation

Digital innovation in healthcare promises much. But potential and realisation are two very different things.

Researchers at Stanford in the US, for example, have developed an AI algorithm designed to diagnose skin cancer[1]. AI diagnosis was compared with that of 21 dermatologists and it matched the efficacy of its human counterparts. This has significant implications for patients, particularly those who find it difficult to access healthcare professionals. But the implications don’t stop there.

Read More

Integrating AI and HCI for drug discovery

Bringing new therapeutics to patients is easier said than done due to the enormous intrinsic complexity behind being efficacious and safe.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive